Sökning: WFRF:(Tsoli M)
> (2021) >
The efficacy of abo...
The efficacy of above-label doses of long-acting somatostatin analogues for the management of patients with gastroenteropancreatic tumors
-
- Tsoli, M. (författare)
- Endocrine Unit, 1st Department of Propaedeutic Internal Medicine, Laiko Hospital, National and Kapodistrian University of Athens, Athens, Greece
-
- Daskalakis, Kosmas, 1979- (författare)
- Örebro universitet,Institutionen för medicinska vetenskaper,Region Örebro län,Department of Surgery
-
- Koumarianou, A. (författare)
- Hematology-Oncology Unit, 4th Department of Internal Medicine, Attiko Hospital, National and Kapodistrian University of Athens, Athens, Greece
-
visa fler...
-
- Kolomodi, D. (författare)
- Endocrine Unit, 1st Department of Propaedeutic Internal Medicine, Laiko Hospital, National and Kapodistrian University of Athens, Athens, Greece
-
- Anagnostou, E. (författare)
- Endocrine Unit, 1st Department of Propaedeutic Internal Medicine, Laiko Hospital, National and Kapodistrian University of Athens, Athens, Greece
-
- Kaltsas, G. (författare)
- Endocrine Unit, 1st Department of Propaedeutic Internal Medicine, Laiko Hospital, National and Kapodistrian University of Athens, Athens, Greece
-
visa färre...
-
(creator_code:org_t)
- European Neuroendocrine Association, 2021
- 2021
- Engelska.
-
Ingår i: Journal of neuroendocrinology (Print). - : European Neuroendocrine Association. - 0953-8194 .- 1365-2826. ; 33:S1, s. 146-146
- Relaterad länk:
-
https://urn.kb.se/re...
Abstract
Ämnesord
Stäng
- Introduction: Above-label doses of long-acting somatostatin analogues (SSAs) are increasingly used for the control of secretory syndrome or as anti-proliferative treatment in patients with gastroenteropancreatic neuroendocrine tumors (GEP-NETs).Aim(s): The aim of this study was to evaluate the anti-proliferative effect of increased dose of SSAs in patients with GEP-NETs.Materials and methods: We collected retrospectively the data of patients with GEP-NETs that received SSAs every 3 or 2 weeks, after disease progression on standard 4-weekly doses. We analysed clinical, biochemical and radiographic response data and identified factors that may influence the outcome.Results: We analysed the data of 16 patients. 7 patients suffered from pancreatic NET (pNET) and 9 from small intestinal NET (si-NET). Indications for dose increase were radiographic progression (62,5%), increasing biomarkers (12,5%) or inadequate syndrome control (25%). Among patients with radiographic progression before the escalation of SSA dose, 3 had disease stabilization and 7 eventually progressed radiographically. Median PFSwas 36 months. PNETs were associated with a significantly lower PFS compared to si-NETs (P= 0.041). Patients with NET with a Ki-67 labelling index≤5 displayed a significantly higher PFS (P= 0.047). No significant difference was observed between patients who received above-label SSAs due to clinical/biochemical or radiographic response (P=0.1). In univariate analysis, the Ki-67≤5 was marginally associated with significantly longer PFS (P=0.05).Conclusion: The administration of above-label doses of SSAs maybe a valuable option in patients who progress on the standard 4-weekly regimen, especially in patients with si-NETs or a Ki-67 labelling index≤5.
Ämnesord
- MEDICIN OCH HÄLSOVETENSKAP -- Klinisk medicin -- Cancer och onkologi (hsv//swe)
- MEDICAL AND HEALTH SCIENCES -- Clinical Medicine -- Cancer and Oncology (hsv//eng)
Nyckelord
- neuroendocrine tumor
- somatostatin analogues
- medical treatment
Publikations- och innehållstyp
- vet (ämneskategori)
- art (ämneskategori)
Hitta via bibliotek
Till lärosätets databas